His Secondary hyperparathyroidism study focuses on Cinacalcet and Calcimimetic. His Kidney disease research incorporates elements of Kidney and Renal function. In his research, he undertakes multidisciplinary study on Kidney and Kidney disease. He performs integrative study on Internal medicine and Surgery. Masafumi Fukagawa conducts interdisciplinary study in the fields of Endocrinology and Diabetes mellitus through his research. His Calcium study frequently draws connections to other fields, such as Cinacalcet. He performs integrative study on Parathyroid hormone and Fibroblast growth factor 23 in his works. Masafumi Fukagawa performs multidisciplinary study in the fields of Hyperparathyroidism and Calcitriol via his papers. Masafumi Fukagawa applies his multidisciplinary studies on Calcitriol and Hyperparathyroidism in his research.
A component of his Secondary hyperparathyroidism study involves Cinacalcet and Calcimimetic. He conducts interdisciplinary study in the fields of Calcimimetic and Secondary hyperparathyroidism through his works. Masafumi Fukagawa conducts interdisciplinary study in the fields of Internal medicine and Surgery through his works. He brings together Surgery and Internal medicine to produce work in his papers. Endocrinology connects with themes related to Oxidative stress in his study. Calcium is often connected to Hyperphosphatemia in his work. His research on Hyperphosphatemia frequently links to adjacent areas such as Calcium. With his scientific publications, his incorporates both Parathyroid hormone and Cinacalcet. He performs integrative Kidney disease and Hyperparathyroidism research in his work.
Masafumi Fukagawa is doing genetic studies as part of his Hyperphosphatemia and Renal osteodystrophy and Kidney disease investigations. He undertakes interdisciplinary study in the fields of Renal osteodystrophy and Secondary hyperparathyroidism through his research. His research on Internal medicine often connects related topics like Interquartile range. His Endocrinology study frequently draws connections to other fields, such as Kidney. He undertakes interdisciplinary study in the fields of Kidney and Kidney disease through his research. Masafumi Fukagawa undertakes interdisciplinary study in the fields of Hemodialysis and Dialysis through his works. Masafumi Fukagawa combines Dialysis and Secondary hyperparathyroidism in his studies. Masafumi Fukagawa undertakes interdisciplinary study in the fields of Parathyroid hormone and Hyperparathyroidism through his works. He undertakes multidisciplinary studies into Hyperparathyroidism and Parathyroid hormone in his work.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Area under the curve. He combines Kidney disease and Nephrotic syndrome in his research. In his research, Masafumi Fukagawa performs multidisciplinary study on Nephrotic syndrome and Kidney disease. He integrates Dialysis with Peritoneal dialysis in his research. Masafumi Fukagawa incorporates Peritoneal dialysis and Dialysis in his research. His Vitamin D and neurology research extends to the thematically linked field of Endocrinology. Much of his study explores Vitamin D and neurology relationship to Endocrinology. By researching both Calcium and Phosphate binder, Masafumi Fukagawa produces research that crosses academic boundaries. He performs multidisciplinary study in Phosphate binder and Parathyroid hormone in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.
N Fukuda;H Tanaka;Y Tominaga;M Fukagawa.
Journal of Clinical Investigation (1993)
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Markus Ketteler;Geoffrey A. Block;Pieter Evenepoel;Masafumi Fukagawa.
Kidney International (2017)
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Takashi Shigematsu;Junichiro James Kazama;Takeyoshi Yamashita;Seiji Fukumoto.
American Journal of Kidney Diseases (2004)
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase
Hiroshi Watanabe;Yohei Miyamoto;Daisuke Honda;Hisae Tanaka.
Kidney International (2013)
Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder
Masafumi Fukagawa;Keitaro Yokoyama;Fumihiko Koiwa;Masatomo Taniguchi.
Therapeutic Apheresis and Dialysis (2013)
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients
Hirotaka Komaba;Shunsuke Goto;Hideki Fujii;Yasuhiro Hamada.
Kidney International (2010)
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Francesca Tentori;Mia Wang;Brian A. Bieber;Angelo Karaboyas.
Clinical Journal of The American Society of Nephrology (2015)
Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients
Shohei Nakanishi;Junichiro James Kazama;Tomoko Nii-Kono;Kentaro Omori.
Kidney International (2005)
Cloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor
Chiaki Hidai;Thomas Zupancic;Kalyani Penta;Kalyani Penta;Adel Mikhail.
Genes & Development (1998)
Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
Masafumi Fukagawa;Masafumi Kitaoka;Hung Yi;Naoko Fukuda.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: